PA
PYXS icon

Perceptive Advisors’s Pyxis Oncology PYXS Stock Holding History

Perceptive Advisors’s Portfolio PYXS Stock Details PYXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,178,307
Closed -$2.62M – 123
2025
Q3 		$2.62M Buy
+1,178,307
New +$1.7M 0.08% 78
2025
Q1 		– Sell
-188,462
Closed -$294K – 105
2024
Q4 		$294K Sell
188,462
-320,000
-63% -$923K 0.01% 96
2024
Q3 		$1.87M Buy
+508,462
New +$1.78M 0.04% 95
2022
Q4 		– Sell
-1,528,812
Closed -$3.01M – 105
2022
Q3 		$3.01M Hold
1,528,812
– – 0.09% 94
2022
Q2 		$3.64M Hold
1,528,812
– – 0.11% 84
2022
Q1 		$6.18M Sell
1,528,812
-415,302
-21% -$3.04M 0.12% 96
2021
Q4 		$21.3M Buy
+1,944,114
New +$22.3M 0.33% 65

Other funds holding PYXS

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
GGI
GordonMD Global Investments Beverely Hills, California $144M AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Perceptive Advisors's PYXS Position: Q4 2025 in Review

Perceptive Advisors sold out of Pyxis Oncology (PYXS) in Q4 2025, closing a stake of 1,178,307 shares — an estimated $2.62M sold.

Perceptive Advisors first reported a position in PYXS in Q4 2021 and held it in 7 quarters. The position peaked at $21.3M in Q4 2021. 79 funds tracked by Wall St. Rank hold PYXS as of Q4 2025.

  • Perceptive Advisors reported no remaining Pyxis Oncology position as of Q4 2025 after selling out during the quarter.
  • Perceptive Advisors sold 1,178,307 Pyxis Oncology shares in Q4 2025, an estimated $2.62M.
  • Perceptive Advisors first reported a position in Pyxis Oncology in Q4 2021 and held it in 7 quarters.
  • Perceptive Advisors's Pyxis Oncology position peaked at $21.3M in Q4 2021.
  • 79 funds tracked by Wall St. Rank held Pyxis Oncology as of Q4 2025.

Based on Perceptive Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.